A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups

Autor: Mônica Aparecida Ganazza, Silvia R. Toledo, Carlos Alberto Scrideli, Luiz Gonzaga Tone, Marcos Borato Viana, Maria Lúcia M. Lee, Elisabete Delbuono, José Andrés Yunes, Juliana Godoy Assumpção, Rosane Gomes de Paula Queiroz, Antonio Sergio Petrilli, Silvia Regina Brandalise, Marcela de Araújo, Andrea Biondi
Přispěvatelé: Scrideli, C, Assumpção, J, Ganazza, M, Araújo, M, Toledo, S, Lee, M, Delbuono, E, Petrilli, A, Queiróz, R, Biondi, A, Viana, M, Yunes, J, Brandalise, S, Tone, L
Rok vydání: 2009
Předmět:
Male
medicine.medical_specialty
Neoplasm
Residual

Adolescent
Receptors
Antigen
T-Cell

Kaplan-Meier Estimate
Acute lymphoblastic leukemia
Gastroenterology
Polymerase Chain Reaction
Sensitivity and Specificity
Immunoglobulin kappa-Chains
Antigens
CD

Internal medicine
Acute lymphocytic leukemia
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Child
Childhood Acute Lymphoblastic Leukemia
Survival rate
Proportional Hazards Models
Gene Rearrangement
Hematology
IG
business.industry
Minimal residual disease
Infant
Reproducibility of Results
Gene rearrangement
Precursor Cell Lymphoblastic Leukemia-Lymphoma
medicine.disease
Flow Cytometry
Prognosis
Childhood
medicine.anatomical_structure
Real-time polymerase chain reaction
Treatment Outcome
Child
Preschool

Immunology
Multivariate Analysis
Female
Original Article
Bone marrow
business
Immunoglobulin Heavy Chains
TCR
Zdroj: Haematologica. 94(6)
ISSN: 1592-8721
Popis: Background: Minimal residual disease is an important independent prognostic factor in childhood acute lymphoblastic leukemia. The classical detection methods such as multiparameter flow cytometry and real-time quantitative polymerase chain reaction analysis are expensive, time-consuming and complex, and require considerable technical expertise. Design and Methods: We analyzed 229 consecutive children with acute lymphoblastic leukemia treated according to the GBTLI-99 protocol at three different Brazilian centers. Minimal residual disease was analyzed in bone marrow samples at diagnosis and on days 14 and 28 by conventional homo/heteroduplex polymerase chain reaction using a simplified approach with consensus primers for IG and TCR gene rearrangements. Results: At least one marker was detected by polymerase chain reaction in 96.4% of the patients. By combining the minimal residual disease results obtained on days 14 and 28, three different prognostic groups were identified: minimal residual disease negative on days 14 and 28, positive on day 14/negative on day 28, and positive on both. Five-year event-free survival rates were 85%, 75.6%, and 27.8%, respectively (p
Databáze: OpenAIRE